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Abstract
Background: Concurrent chemo-radiation (CT-RT) is a standard therapy for squamous cell carcinoma of anal canal.
Different clinical and biological factors may potentially affect outcome. We investigated the prognostic role of baseline
hemoglobin (Hb) in a cohort of anal cancer patients submitted to CT-RT with 5-fluorouracil and mitomycin C.
Methods: Up to 161 patients with clinical stage T1-T4/N0-N3/M0 were treated. Response was assessed at 6 weeks and
thereafter at 3, 6 and 12 months. Two different approaches were used:a)simultaneous integrated boost following RTOG
05-29 indications;b)first sequence of 45Gy/25 fractions to the pelvis followed by 9–14.4 Gy/5–8 fractions to the
macroscopic disease. Primary endpoints were progression-free survival (PFS) and overall survival (OS).
Results: On multivariate analysis, pre-treatment Hb level had a significant correlation to OS (HR:0.53;95% CI:0.33–0.87;
p = 0.001), but not to PFS (HR:0.78;95% CI:0.53–1.15; p = 0.12) Patients with pre-treatment Hb≥ 12 g/dl had 5-year PFS
and OS of 82.2%, compared to 29.3% and 32.8% for those below the threshold. The likelihood to achieve a complete
remission increased by 5.6% for every single-unit (g/dl) increase in baseline Hb level over 11 g/dl. On multivariate
analysis, response to treatment had a significant correlation to PFS (incomplete vs complete response – HR:5.43;95% CI:
2.75–10.7; p < 0.0001) and OS (HR: 6.96;95% CI:2.96–16.5; p < 0.0001).
Conclusions: We showed that baseline Hb level is a strong indicator for poor response to RT-CT in anal cancer
patients. A close clinical monitoring for incomplete response to treatment should be advised in patients with low pre-
treatment Hb. The hypothesis that the preservation of adequate Hb level during treatment may lead to a better
outcome needs prospective evaluation.
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Background
Anal cancer is considered a rare tumor, accounting for
6% of all malignancies arising in the ano-rectal region
[1]. Concurrent chemo-radiation (CT-RT) is the stand-
ard therapeutic option in this setting, providing consist-
ent clinical outcomes [2, 3]. Prospective trials reported
loco-regional recurrence (LRR) rates ranging from 60%
to 80% and overall survival (OS) rates from 65% to 78%
at 3–5 years, depending on disease and patient
characteristics [4–8]. Given the relatively infrequent oc-
currence of squamous cell carcinoma of the anal canal,
the correlation between clinical factors and outcome has
always been challenging to assess [9]. Most of the factors
explored are related to tumor such as size and nodal sta-
tus, while patient features are mostly related to gender
and race [10]. Some of the randomized phase III trials
who set the standard for the treatment of anal cancer,
such as the European Organization for Research and
Treatment of Cancer (EORTC) trial 22861, the Radio-
therapy and Oncology Group (RTOG) trial 98-11 and
the Anal Cancer Trial-I study (ACT-I) provided analyses
on prognostic factors [5, 7, 11]. The EORTC 22861 has
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shown that male sex, nodal involvement and skin ulcer-
ation are independent predictors of LRR and OS [5].
The RTOG 98–11 trial found out a significant correl-
ation between male sex and nodal involvement and LRR
and established tumor size (> 5 cm) as an independent
predictor of disease-free-survival (DFS) and OS [12].
Mature outcomes from the ACT-I trial supported evi-
dence for palpable lymphnodes and male sex as prog-
nostic factors for LRR and OS and interestingly, showed
that lower baseline hemoglobin levels could predict for
the risk of cancer-related death and death from any
cause [11]. It is a common clinical observation that
anemia is frequent in cancer patients [13]. This could
substantially increase the proportion of hypoxic cancer
cells, leading to an intrinsic resistance to radiotherapy
(RT) and chemotherapy (CT), with potential detrimental
effects on treatment outcomes [14]. The impact of
hemoglobin level in anal cancer patients submitted to CT-
RT has been rarely reported [13, 15]. In the present study,
we intended to investigate the influence of different clin-
ical prognostic factors, particularly baseline hemoglobin
(Hb) levels, on treatment outcomes within a cohort of
anal cancer patients submitted to combined RT and CT.
Methods
Patient selection
We retrieved clinical data of patients treated for anal
cancer at the Radiation and Medical Oncology Depart-
ments of 3 Italian institutions, namely University of
Turin, AOU Citta’ della Salute e della Scienza in Turin,
Istituto Scientifico Romagnolo per lo Studio e la Cura
dei Tumori (IRST) in Meldola and Modena Cancer Cen-
ter in Modena. Briefly, all patients had a histologically
confirmed diagnosis of squamous cell carcinoma located
either within the anal canal or margin. Tumor stage was
defined following the indications of the American Joint
Committee on Cancer (2002 version) and patients with
clinical stage T1-T4, N0-N3, M0 were included. Patients
having clinical T1 N0 tumors of the anal margin were
excluded, because generally treated with local excision.
Staging
Pre-treatment clinical evaluation included complete
medical history, physical examination and complete la-
boratory testing. Staging included a chest, abdomen and
pelvis computed tomography (CT) scan and a magnetic
resonance imaging (MRI) of the pelvis with the adjunct
of positron-emission tomography (PET) and/or inguinal
sentinel lymphnode biopsy (SLNB) for systemic and
nodal staging in specific cases.
Patient evaluation
Patients were followed-up according to local practice
and vital status was clinically updated in 2018. Response
to treatment was assessed at 4 time-points, namely at
6 weeks after CT-RT and thereafter at 3, 6 and
12 months [16]. Assessment comprised clinical and
digital rectal examination, pelvic MRI and CT scan of
the upper abdomen and thorax (for staging completion).
Biopsy of any suspicious lesion detected at endoscopic
examination was undertaken. Patients achieving a
complete response (CR) were classified as ‘complete re-
sponders’ in case of clearance of all macroscopic disease
for both primary tumor and regional lymphnodes and
negative biopsy examination (when biopsy was per-
formed). In case of residual tumor on imaging or posi-
tive biopsy after 6 months from CT-RT completion,
patients having less than complete response (IR), were
classified as ‘incomplete responders’. Written informed
consent for treatment was obtained for all patients. The
Ethical Review Board of each Institutional Hospital
approved the present study.
Radiotherapy
Two different approaches were used. At the University
of Turin, patients were submitted to a simultaneous
integrated boost (SIB)- based RT strategy and dose pre-
scription was set according to the RTOG 05-29 indica-
tions modulated on clinical stage at presentation [17].
Patients with cT2N0 disease were given 50.4 Gy in 28
fractions (1.8 Gy daily) to the primary anal tumor, while
the elective nodal volume was prescribed 42 Gy in 28
fractions (1.5 Gy/daily). Patients presenting cT3-T4/N0-
N3 disease were prescribed 54 Gy in 30 fractions (1.8 Gy
daily) to the gross tumor volume, while gross nodal dis-
ease was prescribed 50.4 Gy in 30 fractions (1.68 Gy
daily) if sized ≤ 3 cm or 54 Gy in 30 fractions (1.8 Gy
daily) if > 3 cm. Elective nodal volume was prescribed
45 Gy in 30 fractions (1.5 Gy daily) [14, 15]. Details and
results of this treatment strategy have been previously
published [18–20]. Patients treated at IRST in Meldola
and Modena Cancer Center in Modena were given a
first RT sequence of 45 Gy in 25 fractions (1.8 Gy daily)
delivered over 5 weeks to the macroscopic primary and
nodal tumor and prophylactic volumes (pelvic and in-
guinal nodes, ischio-anal fossa and mesorectum). In the
second sequence, an adjunctive dose of 9–14.4 Gy in 5–
8 fractions was delivered sequentially to the macroscopic
disease up to a total nominal dose of 54–59.4 Gy.
Chemotherapy
All patients were treated according to the Nigro regi-
men. Hence, concomitant CT consisted of 5- fluoroura-
cil (5-FU) (1000 mg/m2/day) given as continuous
infusion for 96 h (days 1–5 and 29–33) combined with
mitomycin C (MMC) (10 mg/m2) given as bolus (days 1
and 29). Mitomycin C was capped at 20 mg maximum
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dose. A total of 2 concurrent cycles were planned for
each patient.
Statistical analysis
Baseline characteristics and clinical endpoints are pre-
sented for all patients. Discrete and continuous variables
were summarized by frequencies and percentages and
using standard measures of central tendency and disper-
sion (mean and standard deviation). The time-to-event
functions were estimated by the Kaplan-Meier product-
limit method. Cox proportional-hazard models were
used to estimate the Hazard Ratios (HR) and the associ-
ated 95% confidence interval (95%CI) both for the uni-
variate and multivariate analysis. We used different
analytic strategies for multivariate model implementa-
tion, namely forward, backward and stepwise ap-
proaches. Wald test and likelihood ratio tests for the
case of nested models were used to assess significance of
both single covariates and the model as a whole. Propor-
tional hazard assumption was tested with visual inspec-
tion of log-log survival curves, plotted scaled
Schoenfen’s residuals and global Kolmogorov-Smirnov
test. Collinearity among independent variables was eval-
uated with Fisher’s exact test, t-test of difference be-
tween means and ANOVA, depending on the nature of
the covariate. The following variables were investigated:
age, gender, tumor and nodal stage, response to treat-
ment, and overall treatment duration. Primary endpoints
were progression free survival (PFS) and OS. Progression
free survival was defined by the time interval between
diagnosis and disease recurrence and/or progression at
any site, death or lost at follow-up. Conversely, OS was
calculated from the date of diagnosis to that of death
from any cause or lost at observation. To assess the
eventual correlation between the chance to achieve a CR
and baseline Hb values, weighted linear regression was
performed with pre-treatment Hb values as independent
variable and the CR rate in predefined group of patients
as dependent variable. Patients were divided in 5 cat-
egories based on baseline Hb values (< 11 g/dl; 11–12 g/
dl; 12–13 g/dl; 13–14 g/dl; > 14 G/dl). All the analyses
were performed with ‘rms’ and ‘survival’ packages of R
software environment (https://www.r-project.org).
Results
A total of 161 patients was analysed from 3 centers (49,
96 and 16 patients, respectively). No significant differ-
ence was found in terms of patient characteristics among
the Institutions. Specifically, mean Hb values at baseline
were 13.20 g/dl (SD: ± 1.44), 12.90 g/dl (SD: ± 1.57) and
12.85 g/dl (SD: ± 2.20), respectively (p = 0.56).
Most of the patients were female (74.5%), HIV nega-
tive (94.4%) with a mean age of 62. Most represented
single global tumor stage was stage II (44.7%), but locally
advanced disease (stage IIIA and IIIB) was seen in up to
46.6% of patients (Table 1). Most of the patients (59.6%)
were treated with a SIB approach, with up to 54 Gy to
the macroscopic tumor disease (60.4%). Those treated
with a sequential boost approach underwent a 9 Gy
boost in 65.1% of the cases.
Almost all patients (98.1%) were given 2 cycles of 5-
FU and MMC. Mean baseline Hb was 13.1 g/dl, while at
the end of treatment mean value was 11.6 g/dl (Table 2).
With anemia as endpoint, acute hematologic toxicity
was ≥ G2 in 10% of the patients (Table 2).
Objective response, evaluated at the planned time-
point after the end of CT-RT, highlighted CR in 76.4% of
Table 1 Patient and tumor characteristics
Variable N (%)
Age
Mean 62
Range 36–83
Sex
Female 120 (74.5)
Male 41 (25.5)
HIV status
Positive 9 (5.6)
Negative 152 (94.4)
T-stage
T1 14 (8.7)
T2 90 (56.0)
T3 40 (24.8)
T4 15 (9.3)
NA 2 (1.2)
N-stage
N0 91 (56.6)
N1 26 (16.1)
N2 34 (21.1)
N3 10 (6.2)
Global stage
I 13 (8.1)
II 72 (44.7)
IIIA 29 (18.0)
IIIB 46 (28.6)
NA 1 (0.6)
Grading
G1 12 (7.5)
G2 86 (53.4)
G3 45 (27.9)
NA 18 (11.2)
N number, T-stage tumor stage, N-stage nodal stage, NA not available
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patients and IR in 23.6%, respectively (Table 3). After a
median follow up of 27 months (range: 1–30), the 3-year
PFS and OS were 71.9% (95% CI:64.2%–80.5%) and 83.
1% (95% CI:76.4%–9.5%), respectively. Five-year PFS and
OS were 71.9% (95% CI: 64.2%–80.5%) and 76.1% (95%
CI: 67.3%–86.0%).
On univariate analysis, considering Hb as a continuous
variable, a higher baseline Hb level significantly affected
PFS (HR:0.57;95% CI:0.39–0.85;p = 0.049) and OS (HR:0.
53;95% CI:0.29–0.96; p = 0.047). Moreover, achieving a
CR after CT-RT significantly affected outcomes (Table
2). Specifically, obtaining a CR was significantly associ-
ated to improved PFS (HR: 5.39;95% CI:2.79–10.40; p <
0.0001) and OS (HR: 6.26;95% CI:2.73–14.40; p < 0.0001)
(Tables 4 and 5).
Results of the multivariate analyses were almost identical
despite the different methods used (forward, backward and
stepwise). On multivariate analysis, pre-treatment Hb level
had a significant correlation to OS (HR:0.53;95% CI:0.33–0.
87;p= 0.001), but not to PFS (HR:0.78;95% CI:0.53–1.15;p=
0.12) (Tables 4 and 5). Response to treatment maintained a
significant correlation to PFS (incomplete vs complete re-
sponse – HR:5.43;95% CI:2.75–10.7; p < 0.0001) and OS (HR:
6.96;95% CI:2.96–16.5; p < 0.0001). Comparison of mean pre-
treatment Hb values in patients having a CR (mean Hb: 13.
2 g/dl; SD: ± 1.12) or IR (mean Hb: 12.2 g/dl; SD: ± 1.86)
showed a significant difference (t-test; p value = 0.043). We
also detected a significant correlation between basal Hb levels
and lymph node status (p= 0.02). Both variables retained stat-
istical significance in the multivariate model, suggesting an
independent effect. In adjunct, the Variance Inflation Factor
(VIF) was 1.1, indicating a low impact of this correlation on
the results of the multivariable model.
Employing a cut-off point at Hb =12 g/dl, patients
with pre-treatment Hb ≥ 12 g/dl had a 5-year PFS of 82.
2%, compared to 29.3% for those with Hb < 12 g/dl (HR:
0.57; 95% CI: 0.39–0.85; p = 0.0047) (Fig. 1). Five-year
OS was 82.2% for patients having Hb ≥ 12 g/dl and 32.
8% for those having baseline Hb < 12 g/dl (HR:0.50; 95%
CI: 0.30–0.83; p = 0.0065) (Fig. 2). Weighted linear re-
gression between CR rate and mean Hb values, showed
a positive trend, with the likelihood of response increas-
ing at higher Hb values (p = 0.11). We categorized pa-
tients in our cohort in 5 groups according to baseline
Hb levels (< 11 g/dl; 11–12 g/dl; 12–13 g/dl; 13–14 g/dl;
> 14 g/dl). Analyzing the slope of the linear regression
curve and related intercept, the lowest Hb level category
had a 55% chance to achieve a CR after CT-RT. Interest-
ingly, this likelihood increased by 5.6% for every single-
unit (g/dl) increase in Hb level (Fig. 3).
Comparing outcomes according to response to treat-
ment, both the 3- and 5-year PFS were 81.5% for pa-
tients achieving a CR compared to 43% for patients with
incomplete response (Fig. 4). Three- and 5-year OS rates
for the same response stratification were 93.1% and 85.
4%, 56.6% and 51.4%, respectively (Fig. 5).
Discussion
As pointed out by Glynne Jones et al., prognostic factors
have to be intended as specific measurable characteris-
tics that can be easily obtained and quantified during ob-
servation within a certain population to be potentially
correlated to measures of clinical outcomes [11]. In anal
cancer, prognostic factors have been described within
retrospective series or randomized prospective phase III
trials [9, 11, 12]. Some depend on tumor characteristics
such as primary tumor dimension and nodal involve-
ment, while others are intrinsic to the patient as for ex-
ample gender. Hemoglobin level is a patient-related
clinical factor that has not been extensively explored in
anal cancer patients [15]. The correlation between Hb
concentration and tumor oxygenation is well-established
in several tumor types, with head and neck cancer being
a paradigmatic example. [21, 22]. Anemia may enhance
tumor hypoxia, increasing tumor cell radio-resistance
and leading to a potentially more aggressive tumor
phenotype [11]. This is well-known, for example, in cer-
vical cancer, but evidence is also present for anal malig-
nancies [23, 24]. Interestingly, in the RTOG 98–11
phase III trial, which explored the role of cisplatin con-
current to radiation and that of maintenance therapy,
patients having levels of Hb below 10 g/dl before
randomization were excluded upfront from the study,
because of the potential dismal prognosis [7]. In this
sense, international clinical guidelines (such as those of
the National Comprehensive Cancer Network) suggest
the use of blood transfusion in symptomatic patients
Table 2 Hemoglobin levels and grade of anemia
Hb values
Pre-treat Post-treat
Mean (g/dl) 13.11 11.63
Range (g/dl) 7.63–16.22 8.44–14.71
Anemia (CTCAE v4.02) - N(%)
NA G0-G1 G2-G3
10 (6.2) 135 (83.8) 16 (10)
Hb hemoglobin, g/dl grams/deciliter, pre-treat pre-treatment, post-treat
post-treatment, N number, CTCAE v4.02 Common Toxicity Criteria for Adverse
Effects version 4.02
Table 3 Objective response rate
Objective response
N(%)
CR 123 (76.4)
IR 38 (23.6)
CR complete remission, IR incomplete response
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with Hb levels below 10 g/dl, in order also to potentially
enhance tumor re-oxygenation [25]. Our data seems to
confirm these findings. On univariate analysis, baseline
Hb levels, considered as a continuous variable, had a sig-
nificant correlation to both PFS (HR:0.57;95%CI:0.39–0.
85;p = 0.049) and OS (HR:0.53;95% CI:0.29–0.96; p = 0.
047). Conversely, on multivariate analysis, baseline Hb
was significantly correlated only to OS (HR:0.50;95% CI:
0.31–0.83;p = 0.0051), but not to PFS (HR:0.80;95% CI:0.
48–1.34;p = 0.40). The discrepancy observed for the cor-
relation between pre-treatment Hb and OS vs PFS
prompts to interrogate whether baseline Hb is a real in-
dependent prognostic factor or if it is just a surrogate
parameter for patient’s comorbid conditions or worse
prognostic outcome. Nevertheless, it should be noted
that the results seems to suggest the presence of a cor-
relation trend between Hb and PFS and hence, our hy-
pothesis is that this observation can be due to the
slenderness of the sample size in our study. We also can-
not rule out an effect related to competing causes of
death, as low Hb levels could be related to a ‘frail’ pa-
tient phenotype or worse clinical conditions predispos-
ing to a higher likelihood of death from any cause, not
strictly related to cancer. We also have to notice that we
could detect a significant correlation between nodal in-
volvement and baseline Hb levels. Again, we cannot fully
rule out the possibility that this correlation could ex-
plain, at least partially, the poor PFS and OS related to
Hb levels. However, both nodal statuts and Hb levels
were comprised within the multivariable model, showing
independent statistical significance. Moreover, the VIF
for both PFS and OS showed very low values (< 1.1),
strongly suggesting a limited influence of this correlation
on the final outcome results. In our analysis, we
employed a cut-off point at Hb =12 g/dl, which was able
to allocate patients to different prognostic classes for
both 5-year PFS (82.2% for Hb ≥ 12 g/dl vs 29.3% for Hb
< 12 g/dl) and OS (82.2% for Hb ≥ 12 g/dl vs 32.8.% for
Hb < 12 g/dl). Our data are in line with those of Roldan
et al. who found a significant correlation between pre-
treatment Hb levels and PFS and OS on univariate ana-
lysis, in a series of 72 anal cancer patients treated with
concurrent CT-RT [15]. On multivariate analysis, lowest
quartile pre-treatment Hb was a predictor for PFS, while
pre-treatment Hb level was a significant predictor for
OS. Interestingly, response to treatment at 3 months (to-
gether with nodal involvement and performance status)
was confirmed as a significant predictor for both PFS
and OS. Using baseline Hb values below 12 g/dl as a
cut- off point (only 10% of patients were below the cut-
off ), Hb levels remained significantly associated to OS
Table 4 Univariate and multivariate analysis for Overall Survival
Univariate Analysis Multivariate Analysis
Variable HR (95% CI) p-value HR (95% CI) p-value
Age > 65 1.44 (0.64–2.43) 0.58 NA NA
Male sex 2.23 (1.42–3.05) 0.01 3.66 (1.56–8.60) 0.002
G3 vs G1
G2 vs G1
1.36 (0.58–3.21)
0.33 (0.03–2.92)
0.29
0.32
NA NA
T3-T4 vs T1-T2 1.94 (0.88–4.25) 0.12 NA NA.
N + ve vs N -ve 2.11 (1.31–2.90) 0.02 2.25 (1.00–5.17) 0.049
RT total dose 1.42 (0.87–2.33) 0.16 NA NA
Boost: yes vs no 1.72 (0.40–7.35) 0.47 NA NA
OTT > 42 days 1.75 (0.86–2.65) 0.19 NA NA
Hb 0.5 (0.30–0.83) 0.006 0.53 (0.33–0.87) 0.001
Response 6.26 (2.73–14.40) < 0.0001 6.96 (2.96–16.50) < 0.0001
RT Radiotherapy, Hb Basal haemoglobin levels (gr/dl), Boost Radiotherapy boost: given vs not, Response Incomplete response vs complete response, OTT Total
legth of chemo-radiation treatment, N node, +ve positive, −ve negative, HR hazard ratio, CI confidence interval, NA not available
Table 5 Univariate and multivariate analysis for Progression
Free Survival
Univariate Analysis Multivariate Analysis
Variable HR (95% CI) p-value HR (95%CI) p-value
Age > 65 1.04 (0.39–1.70) 0.82 NA NA
Male sex 1.17 (0.44–1.90) 0.52 NA NA
G3 vs G1
G2 vs G1
1.87 (0.90–3.88)
1.76 (0.51–6.10)
0.92
0.38
NA
NA
NA
NA
T3-T4 vs T1-T2 1.73 (0.89–3.33) 0.11 NA NA
N + ve vs N -ve 2.16 (1.18–3.96) 0.012 1.98 (1.01–3.88) 0.046
RT total dose 1.12 (0.79–1.58) 0.52 NA NA
Boost: yes vs no 0.84 (0.32–2.18) 0.72 NA NA
OTT > 42 days 1.18 (0.53–1.85) 0.38 NA NA
Hb 0.57 (0.39–0.85) 0.005 0.78 (0.53–1.15) 0.12
Response 5.39 (2.79–10.4) < 0.0001 5.43 (2.75–10.70) < 0.0001
RT Radiotherapy, Hb Basal haemoglobin levels (gr/dl), Boost Radiotherapy
boost: given vs not, Response Incomplete response vs complete response, OTT
Total legth of chemo-radiation treatment, N node, +ve positive, −ve negative,
HR hazard ratio, CI confidence interval, NA not available
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(log-rank p = 0.003) and PFS (log-rank p < 0.0001). In
general, patients with pre-treatment Hb values in the
lowest quartile had significantly worse PFS and OS than
those whose values were in the 3 higher quartiles. A
similar threshold was also found by Kapacee et al., in
their series of 148 anal cancer patients treated CT-RT
within the ACT-II trial (50.4 Gy/28 fractions delivered
over 38 days concomitant to 5-FU and either MMC or
DDP), where a pre-treatment Hb level < 13 g/dl was
found to predict for lower distant metastasis and cancer-
specific survival (p < 0.05) [26]. Given the impact of both
CR and baseline Hb level on treatment outcomes, we
tried to quantify the relationship between these 2 clinical
variables. After clustering patients in different groups
Fig. 1 Progression free survival by baseline hemoglobin level
Fig. 2 Overall survival by baseline hemoglobin level
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based on baseline Hb levels, we analyzed the slope of
the linear regression curve and the intercept. The lowest
Hb level category has a 55% chance to achieve a CR after
CT-RT. Interestingly, this likelihood increases by 5.6%
for every single-unit (g/dl) increase in Hb level. In our
series response to treatment was found to be an inde-
pendent predictor of PFS and OS, while baseline Hb
level was found to independently predict OS but not
PFS. Nevertheless, clinical response and baseline Hb
seem to have a synergistic effect in determining survival,
with higher pre-treatment Hb increasing the chance to
achieve a CR and thus potentially affecting survival. This is
in line with data coming from the ACT-I randomized phase
III trial, which compared exclusive radiation to 5-FU/MMC-
based concurrent CT-RT. In the analysis of prognostic fac-
tors performed within the study, baseline Hb level was
shown as an independent prognostic factor for anal cancer-
related death [11]. After adjusting for sex and lymphnode
Fig. 3 Complete response rate plotted against baseline hemoglobin level
Fig. 4 Progression free survival by response to concurrent chemo-radiation
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status, Glynne-Jones et al. demonstrated that, on average, a
single-unit (g/dl) increase in Hb was associated to a 19% re-
duction in the risk of anal cancer death [11].
In our study pre-treatment Hb levels were significantly
correlated to overall survival. The HR we found at multi-
variate analysis (HR:0.5), was similar to that previously
reported in other oncological settings [14]. That means
that every patient has a 50% decrease in the risk of death
at each time-point for a single unit increase in Hb. Inter-
estingly, such an effect is also observed for Hb levels
above 11 g/dl, suggesting that even a slight, subclinical
decrease in baseline Hb could significantly impair prog-
nosis. Hemoglobin level is also associated to the likeli-
hood of achieving a CR, which was found to be as the
strongest independent prognostic factor for survival.
The chance to achieve a CR increases by 5.6% for every
single-unit (g/dl) increase in Hb level. On the contrary,
lower Hb levels do predict for worse outcome. We can-
not fully exclude other causes for the dismal prognosis
seen in anemic patients. Baseline hemoglobin levels can
be a mere consequence of a more aggressive biology of
the tumor or a surrogate for patient’s frailty or comorbid
state. But at the same time baseline Hb levels seem to
strongly predict for a higher likelihood to achieve a
complete response to treatment. Probably, both aspects
play a role in the final clinical outcome of the patient.
Conclusions
Our study has several limitations. At first, the small
sample size did not allow us to perform subset analyses
to better investigate the correlation between baseline Hb
levels and other clinical variables potentially affecting
treatment results. Secondly, the retrospective frame did
not allow us to robustly check for eventual confounding
factors. Another element, potentially influencing the re-
sults, is the different RT approach employed in the par-
ticipating centers (simultaneous integrated boost vs
sequential strategies), which implies different overall
treatment times. The differential treatment length may
be a factor influencing the relative strength in the correl-
ation between baseline Hb and clinical outcomes. More-
over, we were not able to discriminate neither the
different causes of anemia in our patients (iron defi-
ciency, bleeding, nutritional status or chronic disease)
nor the consequent treatment strategies employed to
correct the deficit. This would have helped to better put
into perspective the correlation between anemia and
clinical outcomes [27]. Finally, we were not able to con-
sistently track treatment breaks and modifications to
have an idea on the eventual association with Hb levels
and to monitor the clinical meaningfulness of the par-
ameter [28, 29]. Nevertheless, we were able to demon-
strate that low baseline Hb levels are correlated to a
higher likelihood to experience an incomplete response
after treatment. Hence, objective response after CT-RT
should be carefully monitored in these patients. Consid-
ering the poor prognosis associated to a lack of objective
response to treatment and the significant impact on
quality of life due to colostomy for those submitted to
salvage surgery, we encourage oncologists to consider as
a clinical priority the preservation of adequate Hb levels
before starting CT-RT, but, possibly, during all phases of
Fig. 5 Overall survival by response to concurrent chemo-radiation
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active therapy. To fully confirm this preliminary hypoth-
esis, a prospective study having anemia correction as
intervention is needed.
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